Surreal image of scientific glassware cradling a mother and child, symbolizing IVF success.

Unlocking IVF Success: How a New Drug Offers Hope to Aspiring Parents

Mira Elwood monogram
Mira Elwood in Health & Wellness October 2026 • 3 min read.

"Nolasiban Shows Promising Results in Improving Embryo Implantation Rates"


For couples navigating the challenging path of infertility, In Vitro Fertilization (IVF) offers a beacon of hope. While IVF technology has advanced significantly, a successful pregnancy is not always guaranteed. One of the most critical steps is ensuring the embryo successfully implants in the uterus, a process that can be influenced by various factors.

Now, a promising new drug called nolasiban is offering renewed hope to those undergoing IVF. Clinical trials have shown that nolasiban can significantly improve embryo implantation rates, leading to higher success rates for aspiring parents. This breakthrough represents a significant step forward in fertility treatment.

This article delves into the science behind nolasiban, explores the results of the clinical trials, and examines the potential impact of this innovative drug on the future of IVF and fertility treatments.

AI Search Multiple angles on this topic

Nolasiban’s IVF Research

The source describes a summary of data from three randomized clinical trials in women undergoing IVF, alongside a mechanism-of-action study in healthy volunteers. The research examined nolasiban, an oral oxytocin receptor antagonist being developed to improve pregnancy and live-birth rates after fresh embryo transfer. The source does not provide specific success-rate figures.

IVF Factors and Nolasiban’s Evaluation

The source identifies embryo quality, transfer technique, the number of embryos used, uterine receptivity to implantation, and the ability to sustain a pregnancy as factors that can influence IVF success. A Phase 3 study registered as NCT03758885 was designed to compare nolasiban with placebo in 820 women undergoing fresh single-blastocyst transfer after IVF or ICSI. It was prospective, randomized, parallel-group, double-blind, and placebo-controlled, and aimed to confirm efficacy and safety for pregnancy and live-birth rates. A separate mechanism-of-action study reported more marked effects at 1800 mg than at 900 mg and supported testing higher doses in IVF patients.

Nolasiban’s Development Milestones

On March 5, 2019, Obseva provided timelines for key milestones in the development of nolasiban, described as a first-in-class oral oxytocin receptor antagonist. The candidate was intended to improve clinical pregnancy and live-birth rates in women undergoing IVF or ICSI, with development focused on inhibiting uterine contractions during single embryo transfer. The supplied article about the drug also describes it as being studied for its potential to improve embryo implantation, but gives no additional milestone dates.

Nolasiban: A New Hope for IVF Success

Surreal image of scientific glassware cradling a mother and child, symbolizing IVF success.

Nolasiban works by blocking the hormone oxytocin. Oxytocin is often associated with labor contractions, but it also plays a role in uterine contractions that can interfere with embryo implantation. By blocking oxytocin, nolasiban helps to relax the uterus, increase blood flow, and create a more receptive environment for the embryo.

The clinical trial, involving nearly 800 women at fertility clinics across Europe, demonstrated the potential of nolasiban. Participants took either nolasiban or a placebo four hours before their embryo transfer. The results were compelling: almost 45% of women in the nolasiban group went on to have a baby, compared to only 33% in the placebo group.

  • Improved Implantation Rates: Higher percentage of successful pregnancies.
  • Increased Blood Flow: Relaxation of uterus muscles aids blood flow.
  • Hormone Regulation: Balances the effects of oxytocin, leading to better results.
AI Search Multiple angles on this topic

A Phase 3 Setback

Obseva discontinued its nolasiban (OBE001) IVF program in 2019 after the candidate failed to meet the primary endpoint of increasing ongoing pregnancy at 10 weeks in the IMPLANT4 clinical trial. The report described nolasiban as well tolerated despite the efficacy failure. Another source describes a Phase 3 study planned to test nolasiban against placebo in 820 women undergoing fresh single-blastocyst transfer after IVF or ICSI. A separate source claims nolasiban suppresses an oxytocin-activated pro-inflammatory cascade in vitro, whereas atosiban may do so only partially; this is a reported laboratory comparison, not evidence that nolasiban improved clinical outcomes.

Evidence for Further Evaluation

An analysis of nolasiban reports that its findings support the hypothesis that oxytocin receptor antagonism at the time of embryo transfer can increase pregnancy rates following IVF. The authors also say that the clinical and population pharmacokinetic data support future evaluation of higher doses or alternate regimens in women undergoing embryo transfer. The source presents these findings as support for further evaluation, rather than establishing that a higher dose or alternate regimen improves outcomes.

These findings suggest that nolasiban could significantly improve the chances of a successful pregnancy for women undergoing IVF. Ernest Loumaye at ObsEva, the firm developing the drug, described the results as potentially "the biggest advance in IVF in 25 years."

Looking Ahead: The Future of Nolasiban and IVF

While the initial results are promising, further research is crucial. Another trial is planned, and the drug may be available by late 2020. Experts advise caution until the full experimental details are released. Nolasiban represents a hopeful advancement in IVF treatment. By improving embryo implantation rates, this innovative drug offers the potential to significantly increase the chances of pregnancy for aspiring parents. As research continues, nolasiban could become a standard part of IVF protocols, bringing joy and hope to countless families.

AI Search Multiple angles on this topic

Three-Trial Analysis

A publication record describes an analysis of three randomized clinical trials of the oxytocin receptor antagonist nolasiban in women undergoing embryo transfer following IVF. Its stated focus is the effect of nolasiban on pregnancy rates. The supplied source information does not include the analysis’s numerical results or conclusions.

The IMPLANT 2 Trial

IMPLANT 2 is described as a Phase 3, randomized, double-blind clinical trial comparing nolasiban with placebo. It assesses whether nolasiban can improve pregnancy rates in patients undergoing IVF or ICSI due to low fertility. The supplied source does not provide the trial’s results or a completion date.

IMPLANT 4: pregnancy rates were close

  • 39.1% vs 40.5% ongoing pregnancy at 10 weeksIn IMPLANT 4, ongoing pregnancy at 10 weeks was 39.1% with placebo and 40.5% with nolasiban; the difference was not statistically significant (p = 0.745).[1]Caveat: The trial did not meet its primary endpoint of increasing ongoing pregnancy at 10 weeks.

What the nolasiban results add up to

The results point in different directions: the earlier IMPLANT 2 trial reported a live-birth increase, while IMPLANT 4 did not meet its primary pregnancy endpoint. Taken together, the findings do not establish a consistent clinical benefit.[1]

What remains unanswered about nolasiban

  • Would effects vary among patients with different uterine contraction rates at embryo transfer? The company described this population as a possible focus for repositioning, but the cited results do not establish an outcome for that group.[1]

Sources

  1. 2019-03-05_ObsEva Annual Report 2018.indd (www.annualreports.com)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

How does Nolasiban improve the chances of successful IVF?

Nolasiban is a medication designed to enhance the success rates of In Vitro Fertilization (IVF) by improving the embryo implantation process. It functions by blocking oxytocin, a hormone that can cause uterine contractions. By blocking oxytocin, Nolasiban helps relax the uterus and increase blood flow, creating a more favorable environment for embryo implantation. This can lead to a higher chance of successful pregnancy for women undergoing IVF.

2

What were the key results of the clinical trials for Nolasiban?

Clinical trials involving nearly 800 women across Europe showed that approximately 45% of women who took Nolasiban before embryo transfer had a baby, compared to only 33% in the group that received a placebo. These results suggest that Nolasiban can significantly improve pregnancy rates in IVF treatments. The participants took either Nolasiban or a placebo four hours before their embryo transfer. The results showed a notable increase in successful pregnancies in the Nolasiban group.

3

What is the mechanism of action for Nolasiban and how does it facilitate embryo implantation?

Nolasiban works by directly targeting and blocking the effects of oxytocin on the uterus. Oxytocin can cause uterine contractions that may interfere with the embryo's ability to implant successfully. By blocking oxytocin, Nolasiban helps the uterus relax, which increases blood flow to the uterine lining. This creates a more receptive environment, improving the likelihood of successful embryo implantation and subsequent pregnancy. This mechanism aims to address one of the critical challenges in IVF, which is ensuring the embryo can properly attach and develop.

4

What are the next steps in the research and development of Nolasiban, and when might it become available?

While the initial clinical trial results for Nolasiban are promising, it is important to note that further research is necessary. Another clinical trial is planned to gather more data and confirm the initial findings. Additionally, experts recommend waiting for the full experimental details to be released before drawing definitive conclusions. If the subsequent trials are successful and the drug is approved, Nolasiban could become a standard component of IVF protocols, potentially increasing pregnancy rates for many aspiring parents. The drug may be available by late 2020.

5

What are the broader implications of Nolasiban for the future of fertility treatments and IVF success rates?

The implications of Nolasiban for fertility treatments are substantial. If further research confirms its effectiveness and safety, Nolasiban could revolutionize IVF by significantly increasing embryo implantation rates. This could reduce the emotional and financial burden on couples undergoing IVF, as it would increase their chances of success with each cycle. Moreover, Nolasiban's targeted approach of blocking oxytocin to relax the uterus could pave the way for new research into other factors affecting embryo implantation and potentially lead to the development of additional therapies to improve IVF outcomes. This is described as the 'biggest advance in IVF in 25 years.'

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.